Treating Patients with Non-Driver Mutations mNSCLC

Experts share insights on the use chemotherapy and immunotherapy in driver-negative patients, along with the use of PD-L1 inhibitors.

Related Keywords

,Precision Medicine ,Bridging Gaps ,Patients Without Driver Mutations ,Non Driver Mutations ,Profile ,Squamous Cancer ,Egfr ,Driver Alterations ,Clinical Bias ,Next Generation Sequencing ,Immunotherapy ,